Methamphetamine impairs IgG1-mediated phagocytosis and killing of Cryptococcus neoformans by J774.16 macrophage- and NR-9640-microglia-like cells | Infection and Immunity
Our findings suggest that METH abrogates immune cellular and molecular functions and may be deadly to phagocytic cells, which may result in increased susceptibility of users to acquire infectious diseases. Source: Methamphetamine impairs IgG1-mediated phagocytosis and...
read moreIncrease in Methamphetamine Use by Iowans (11/26/18)
Meth is now the second most reported drug by adults at admission to treatment, moving ahead of marijuana for the first time. Source: Increase in Methamphetamine Use by Iowans...
read moreU.S. GAO – Adolescent and Young Adult Substance Use: Federal Grants for Prevention, Treatment, and Recovery Services and for Research
For National #MethAwarenessDay, read and listen to how federal grants are targeted to prevent and treat substance abuse among adolescents and young adults. Source: U.S. GAO - Adolescent and Young Adult Substance Use: Federal Grants for Prevention, Treatment, and...
read moreDeveloping Novel Therapeutics for Addiction
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 is being studied in an upcoming Phase 2 proof-of-concept study (STAMPOUT). We are also developing a novel vaccine (IXT-v100) against methamphetamine.
Methamphetamine impairs IgG1-mediated phagocytosis and killing of Cryptococcus neoformans by J774.16 macrophage- and NR-9640-microglia-like cells | Infection and Immunity
Our findings suggest that METH abrogates immune cellular and molecular functions and may be deadly to phagocytic cells, which may result in increased susceptibility of users to acquire infectious diseases. Source: Methamphetamine impairs IgG1-mediated phagocytosis and...
read moreIncrease in Methamphetamine Use by Iowans (11/26/18)
Meth is now the second most reported drug by adults at admission to treatment, moving ahead of marijuana for the first time. Source: Increase in Methamphetamine Use by Iowans...
read moreU.S. GAO – Adolescent and Young Adult Substance Use: Federal Grants for Prevention, Treatment, and Recovery Services and for Research
For National #MethAwarenessDay, read and listen to how federal grants are targeted to prevent and treat substance abuse among adolescents and young adults. Source: U.S. GAO - Adolescent and Young Adult Substance Use: Federal Grants for Prevention, Treatment, and...
read moreDeveloping Novel Therapeutics for Addiction
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 is being studied in an upcoming Phase 2 proof-of-concept study (STAMPOUT). We are also developing a novel vaccine (IXT-v100) against methamphetamine.